Further evidence that hyperhomocysteinemia and methylenetetrahydrofolate reductase C677T and A1289C polymorphisms are not risk factors for schizophrenia
- 1 September 2005
- journal article
- research article
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 29 (7) , 1169-1174
- https://doi.org/10.1016/j.pnpbp.2005.07.001
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Folate, Homocysteine, and Negative Symptoms in SchizophreniaAmerican Journal of Psychiatry, 2004
- The 5,10-methylenetetrahydrofolate reductase C677T polymorphism interacts with smoking to increase homocysteineAtherosclerosis, 2004
- Regulation of Serum Paraoxonase Activity by Genetic, Nutritional, and Lifestyle Factors in the General PopulationClinical Chemistry, 2003
- Genotype and haplotype distributions of MTHFR 677C>T and 1298A>C single nucleotide polymorphisms: a meta-analysisJournal of Human Genetics, 2003
- Elevated Homocysteine Levels in Young Male Patients With SchizophreniaAmerican Journal of Psychiatry, 2002
- Association between the methylenetetrahydrofolate reductase 677C→T missense mutation and schizophreniaMolecular Psychiatry, 2000
- Methylenetetrahydrofolate reductase variant and schizophrenia/depressionAmerican Journal of Medical Genetics, 1997
- A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductaseNature Genetics, 1995
- Enhancement of recovery from psychiatric illness by methylfolateThe Lancet, 1990
- Validity of the scaled version of the General Health Questionnaire (GHQ-28) in a Spanish populationPsychological Medicine, 1986